Andreas Lindblom
Founding Partner and CEO @ Sciety
Stockholm, Sweden
Andreas Lindblom is a venture - series unknown investor at Sciety in Stockholm focused on Health Care and Medical. Former CEO at Spring Securities, co-founder of Karolinska Center for Advanced Medical Simulation and Training, group manager at Sales & Service at Itivity, and physiotherapist at the Karolinska Institute. Andreas holds degrees in physics and physiotherapy.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries Andreas Lindblom invests in
Stages Andreas Lindblom invests in
Countries Andreas Lindblom invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (38%)
- Medical 3 (23%)
- Biotechnology 3 (23%)
- Genetics 2 (15%)
- Pharmaceutical 2 (15%)
Stage
- Venture - Series Unknown 5 (38%)
- Series A 2 (15%)
- Series B 1 (8%)
- Equity Crowdfunding 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Everdrone is at the forefront of a new era in public safety, where emergency drones are a critical and integrated part of everyday life. Our drones provide critical support to emergency response organisations by reaching incident scenes faster than any ground unit to gather vital information and deliver life-saving medical equipment. | $3.9M / Venture - Series Unknown / Mar 19, 2026 | ||
| NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $9.8M / Venture - Series Unknown / Feb 11, 2026 | ||
| TIRmed Pharma develops drug candidates addressing major clinical needs. | $4.7M / Venture - Series Unknown / Apr 09, 2025 | ||
| PeptiSystems focuses on manufacturing and supplying instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics. | $4.1M / Venture - Series Unknown / Dec 20, 2024 | ||
| Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $1.4M / Series A / Feb 15, 2024 | ||
| NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $4.9M / Venture - Series Unknown / Nov 09, 2023 | ||
| Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $5.8M / Series A / Apr 24, 2023 | ||
| Encare was established in 2009 to implement the ERAS Protocols on a global basis by- providing training to health care professionals on the ERAS Protocols- providing an interactive and web-based information system for evidence based - best practice management (EBM)The company has developed an interactive, user-friendly interface forthe collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence.The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings.Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States.The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery. | $2.4M / Venture - Series Unknown / Sep 19, 2022 | ||
| Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $3.5M / Series B / May 31, 2022 | ||
| SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine,provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits.The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity. | $12.4M / Series A / Jun 29, 2021 | ||
| See all 13 investments → | |||
Co-Investors
About Sciety
Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations,helping to bring breakthroughs in healthcare to people all over the world.Investment areas: biotechnology, pharmaceuticals, medical technology and health tech.Deal size: 1 – 15 MEUR.Sciety AB is regulated by Finansinspektionen (the Swedish financial supervisory authority) and is a member of the Swedish Private Equity & Venture Capital Association (SVCA) and SwedenBIO (trade association for the Swedish life science industry).
Sciety Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charlotte Smirnova Lindblom
Corporate Communications Manager
|
|||
Erik Hjelmstedt
Chairman
|
|||
|
Andreas Lindblom
Founding Partner and CEO
|
|||
Bengt Julander
Senior Advisor
|
|||
Christina Sterner
Back Office Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andreas Lindblom invest in?
Andreas Lindblom invests primarily in Health Care, Medical and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 13 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andreas Lindblom?
Public channels for Andreas Lindblom include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andreas Lindblom last invest?
The most recent investment recorded for Andreas Lindblom closed in Mar 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
